Literature DB >> 11772443

Genotyping methods to detect a unique neuroprotective factor (Wld(s)) for axons.

Weiqian Mi1, Laura Conforti, Michael P Coleman.   

Abstract

The slow Wallerian degeneration mouse, C57BL/Wld(s), carries a dominant mutation that delays Wallerian degeneration in the distal stump of an injured axon. The protective gene has been identified and also found to protect axons from the neurotoxin vincristine. Therefore, it is important to determine whether it has a widespread application to protect axons in neurological disease. In principle, this can be done by crossing Wld(s) to neurological mutant mice, but first a method is needed to track the inheritance of the neuroprotective Wld(s) allele. Due to the complex nature of the mutation, there is no simple method to distinguish Wld(s) homozygotes, heterozygotes and wild-type mice. Therefore, we report a genotyping method for Wld(s) based upon pulsed field gel electrophoresis (PFGE) and compare it with the alternatives of PCR and Southern blotting. The effect of the Wld(s) mutation on axon degeneration in diverse inherited pathologies, and the consequence for symptoms, can now be investigated.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11772443     DOI: 10.1016/s0165-0270(01)00501-5

Source DB:  PubMed          Journal:  J Neurosci Methods        ISSN: 0165-0270            Impact factor:   2.390


  8 in total

1.  The Wlds mutation delays robust loss of motor and sensory axons in a genetic model for myelin-related axonopathy.

Authors:  Mohtashem Samsam; Weiqian Mi; Carsten Wessig; Jürgen Zielasek; Klaus V Toyka; Michael P Coleman; Rudolf Martini
Journal:  J Neurosci       Date:  2003-04-01       Impact factor: 6.167

2.  The neuroprotective factor Wlds does not attenuate mutant SOD1-mediated motor neuron disease.

Authors:  Christine Vande Velde; Michael L Garcia; Xinghua Yin; Bruce D Trapp; Don W Cleveland
Journal:  Neuromolecular Med       Date:  2004       Impact factor: 3.843

3.  The Wld(S) mutation delays anterograde, but not retrograde, axonal degeneration of the dopaminergic nigro-striatal pathway in vivo.

Authors:  Hsiao-Chun Cheng; Robert E Burke
Journal:  J Neurochem       Date:  2010-02-01       Impact factor: 5.372

4.  Age-dependent synapse withdrawal at axotomised neuromuscular junctions in Wld(s) mutant and Ube4b/Nmnat transgenic mice.

Authors:  Thomas H Gillingwater; Derek Thomson; Till G A Mack; Ellen M Soffin; Richard J Mattison; Michael P Coleman; Richard R Ribchester
Journal:  J Physiol       Date:  2002-09-15       Impact factor: 5.182

5.  The Wallerian degeneration slow (Wld(s)) gene does not attenuate disease in a mouse model of spinal muscular atrophy.

Authors:  Ferrill F Rose; Philip W Meehan; Tristan H Coady; Virginia B Garcia; Michael L Garcia; Christian L Lorson
Journal:  Biochem Biophys Res Commun       Date:  2008-08-03       Impact factor: 3.575

6.  Wld(S) reduces paraquat-induced cytotoxicity via SIRT1 in non-neuronal cells by attenuating the depletion of NAD.

Authors:  Qiujing Yu; Ting Wang; Xuexia Zhou; Jingxia Wu; Xingmiao Chen; Yang Liu; Dongmei Wu; Qiwei Zhai
Journal:  PLoS One       Date:  2011-07-05       Impact factor: 3.240

7.  WldS enhances insulin transcription and secretion via a SIRT1-dependent pathway and improves glucose homeostasis.

Authors:  Jingxia Wu; Fang Zhang; Menghong Yan; Dongmei Wu; Qiujing Yu; Yi Zhang; Ben Zhou; Michael W McBurney; Qiwei Zhai
Journal:  Diabetes       Date:  2011-10-13       Impact factor: 9.461

8.  Design of a novel quantitative PCR (QPCR)-based protocol for genotyping mice carrying the neuroprotective Wallerian degeneration slow (Wlds) gene.

Authors:  Thomas M Wishart; Stephen Hf Macdonald; Philip E Chen; Michael J Shipston; Michael P Coleman; Thomas H Gillingwater; Richard R Ribchester
Journal:  Mol Neurodegener       Date:  2007-10-30       Impact factor: 14.195

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.